US2010104531A1PendingUtilityA1

Homogeneous preparations of il-28 and il-29

75
Assignee: ZYMOGENETICS INCPriority: Aug 7, 2003Filed: Oct 1, 2009Published: Apr 29, 2010
Est. expiryAug 7, 2023(expired)· nominal 20-yr term from priority
Inventors:Lowell J. BradyKevin M. KlucherChung ChanDennis L. DongHong LiuPaul O. SheppardThomas R. Bukowski
A61P 37/08A61P 31/14A61P 31/20A61P 31/12A61P 29/00A61P 1/16C07K 14/555Y10S435/975C07K 2319/00C07K 14/54A61K 38/20A61K 38/00Y10S435/81
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Claims

exact text as granted — not AI-modified
1 . An isolated polypeptide consisting of an amino acid sequence having at least 98% sequence identity to amino acid residues 1-176 of SEQ ID NO:159, wherein the polypeptide has anti-hepatitis B or C activity. 
     
     
         2 . The isolated polypeptide of  claim 1 , wherein the polypeptide has at least 99% sequence identity to amino acid residues 1-176 of SEQ ID NO:159. 
     
     
         3 . The isolated polypeptide of  claim 1 , wherein the polypeptide is conjugated to a polyethylene glycol moiety. 
     
     
         4 . The isolated polypeptide of  claim 3 , wherein the polyethylene glycol moiety is mPEG propionaldehyde. 
     
     
         5 . The isolated polypeptide of  claim 4 , wherein the mPEG propionaldehyde has a molecular weight of about 20 kD. 
     
     
         6 . The isolated polypeptide of  claim 4 , wherein the mPEG propionaldehyde is linear. 
     
     
         7 . An isolated polynucleotide encoding a polypeptide wherein the encoded polypeptide consists of an amino acid sequence having at least 98% sequence identity to amino acid residues 1-176 of SEQ ID NO:159, wherein the polypeptide has anti-hepatitis B or C activity. 
     
     
         8 . The isolated polynucleotide of  claim 7 , wherein the encoded polypeptide has at least 99% sequence identity to amino acid residues 1-176 of SEQ ID NO:159. 
     
     
         9 . An expression vector comprising the following operably linked elements:
 a transcription promoter;   a DNA segment encoding the polypeptide of  claim 1 ; and   a transcription terminator.   
     
     
         10 . An expression vector comprising the following operably linked elements:
 a transcription promoter;   a DNA segment encoding the polypeptide of  claim 2 ; and   a transcription terminator.   
     
     
         11 . A cultured cell comprising the expression vector of  claim 9  or  10 , wherein the cell expresses the polypeptide encoded by the DNA segment. 
     
     
         12 . A method of producing a polypeptide comprising:
 culturing a cell comprising the expression vector of  claim 9  or  10 , wherein the cell expresses the polypeptide encoded by the DNA segment; and   recovering the expressed polypeptide.   
     
     
         13 . A formulation comprising:
 an isolated polypeptide consisting of an amino acid sequence having at least 98% sequence identity to amino acid residues 1-176 of SEQ ID NO:159, wherein the polypeptide has anti-hepatitis B or C activity; and   a pharmaceutically acceptable vehicle.   
     
     
         14 . The formulation of  claim 13 , wherein the polypeptide has at least 99% sequence identity to amino acid residues 1-176 of SEQ ID NO:159. 
     
     
         15 . The formulation of  claim 13 , wherein the polypeptide is conjugated to a polyethylene glycol moiety. 
     
     
         16 . The formulation of  claim 15 , wherein the polyethylene glycol moiety is mPEG propionaldehyde. 
     
     
         17 . The formulation of  claim 16 , wherein the mPEG propionaldehyde has a molecular weight of about 20 kD. 
     
     
         18 . The formulation of  claim 16 , wherein the mPEG propionaldehyde is linear. 
     
     
         19 . A kit comprising the formulation as in any one of  claims 13 - 18 . 
     
     
         20 . An isolated polypeptide comprising an amino acid sequence having at least 95% sequence identity to amino acid residues 1-181 of SEQ ID NO:4, wherein the amino acid residue that corresponds to the cysteine at position 171 of SEQ ID NO:4 is substituted with another amino acid, wherein the amino acid residues that correspond to the cysteine at position 15 and position 112 of SEQ ID NO:4 form a first disulfide bond, wherein the amino acid residues that correspond to the cysteine at position 49 and position 145 of SEQ ID NO:4 form a second disulfide bond, and wherein the polypeptide has anti-hepatitis B or C activity. 
     
     
         21 . The isolated polypeptide of  claim 20 , wherein the amino acid residue that corresponds to the cysteine at position 171 of SEQ ID NO:4 is substituted with a serine, alanine, threonine, valine or asparagine. 
     
     
         22 . The isolated polypeptide of  claim 20 , wherein the amino acid residue that corresponds to the cysteine at position 171 of SEQ ID NO:4 is substituted with a serine. 
     
     
         23 . The isolated polypeptide of  claim 20 , wherein the polypeptide has at least 96% identity to amino acid residues 1-181 of SEQ ID NO:4. 
     
     
         24 . The isolated polypeptide of  claim 20 , wherein the polypeptide further comprises an amino-terminal methionine. 
     
     
         25 . An isolated polynucleotide encoding a polypeptide wherein the encoded polypeptide comprises an amino acid sequence having at least 95% sequence identity to amino acid residues 1-181 of SEQ ID NO:4, wherein the amino acid residue that corresponds to the cysteine at position 171 of SEQ ID NO:4 is substituted with another amino acid, wherein the amino acid residues that correspond to the cysteine at position 15 and position 112 of SEQ ID NO:4 form a first disulfide bond, wherein the amino acid residues that correspond to the cysteine at position 49 and position 145 of SEQ ID NO:4 form a second disulfide bond, and wherein the polypeptide has anti-hepatitis B or C activity. 
     
     
         26 . The isolated polynucleotide of  claim 25 , wherein the amino acid residue that corresponds to the cysteine at position 171 of SEQ ID NO:4 is substituted with a serine, alanine, threonine, valine or asparagine. 
     
     
         27 . The isolated polynucleotide of  claim 25 , wherein the amino acid residue that corresponds to the cysteine at position 171 of SEQ ID NO:4 is substituted with a serine. 
     
     
         28 . The isolated polynucleotide of  claim 25 , wherein the encoded polypeptide has at least 96% sequence identity to amino acid residues 1-181 of SEQ ID NO:4. 
     
     
         29 . The isolated polynucleotide of  claim 25 , wherein the encoded polypeptide further comprises an amino-terminal methionine. 
     
     
         30 . An expression vector comprising the following operably linked elements:
 a transcription promoter;   a DNA segment encoding the polypeptide of  claim 20 ; and   a transcription terminator.   
     
     
         31 . An expression vector comprising the following operably linked elements:
 a transcription promoter;   a DNA segment encoding the polypeptide of  claim 23 ; and   a transcription terminator.   
     
     
         32 . A cultured cell comprising the expression vector of  claim 30  or  31 , wherein the cell expresses the polypeptide encoded by the DNA segment. 
     
     
         33 . A method of producing a polypeptide comprising:
 culturing a cell comprising the expression vector of  claim 30  or  31 , wherein the cell expresses the polypeptide encoded by the DNA segment; and   recovering the expressed polypeptide.   
     
     
         34 . A formulation comprising the polypeptide of  claim 20 , and a pharmaceutically acceptable vehicle. 
     
     
         35 . The formulation of  claim 34 , wherein the encoded polypeptide has at least 96% sequence identity to amino acid residues 1-181 of SEQ ID NO:4. 
     
     
         36 . The formulation of  claim 34 , wherein the polypeptide is conjugated to a polyethylene glycol moiety. 
     
     
         37 . The formulation of  claim 36 , wherein the polyethylene glycol moiety is mPEG propionaldehyde. 
     
     
         38 . The formulation of  claim 37 , wherein the mPEG propionaldehyde has a molecular weight of about 20 kD. 
     
     
         39 . The formulation of  claim 37 , wherein the mPEG propionaldehyde is linear. 
     
     
         40 . A kit comprising the formulation as in any one of  claims 34 - 39 .

Join the waitlist — get patent alerts

Track US2010104531A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.